An exploratory study on the effectiveness of “Calmare therapy” in patients with cancer-related neuropathic pain: A pilot study

Lee, Sang Chul; Park, Keun Suk; Moon, Jee Youn; Kim, Eun Jung; Kim, Yong-Chul; Seo, Hye-Jin; Sung, Ji Youn; Lee, Da Jeong

doi:10.1016/j.ejon.2015.12.001

Cited by 23 publications

(13 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When compared with other studies, our survivors’ interference scores were similar to scores reported by oncology patients experiencing taxane-induced arthralgias and myalgias, 70 but lower than scores reported by oncology patients with bone metastasis 67 or oncology patients with a variety of neuropathic pain conditions. 71 In order to better assess interference with function in the upper extremities, additional items need to be developed for the BPI.…”

Section: Discussionmentioning

confidence: 99%

Chemotherapy-Induced Neuropathy in Cancer Survivors

Miaskowski

Mastick

Paul

et al. 2017

Journal of Pain and Symptom Management

100

View full text Add to dashboard Cite

Context Evidence suggests that chemotherapy-induced neuropathy (CIN) is a significant problem for cancer survivors. However, a detailed phenotypic characterization of CIN in cancer survivors is not available. Objectives To evaluate between group differences in demographic and clinical characteristics, as well as in measures of sensation, function, and postural control, in a sample of cancer survivors who received a platinum and/or a taxane-based CTX regimen and did (n=426) and did not (n=197) develop CIN. Methods Survivors completed self-report questionnaires and underwent objective testing (i.e., light touch, pain sensation, cold sensation, vibration, muscle strength, grip strength, Purdue Pegboard test, Timed Get Up and Go Test, Fullerton Advanced Balance test). Parametric and non-parametric statistics were used to compare between group differences in study outcomes. Results Of the 426 survivors with CIN, 4.9% had CIN only in their upper extremities, 27.0% only in their lower extremities, and 68.1% in both their upper and lower extremities. Demographic and clinical characteristics associated with CIN included: older age, lower annual income, higher body mass index, a higher level of comorbidity, being born prematurely, receipt of a higher cumulative dose of chemotherapy, and a poorer functional status. Survivors with CIN had worse outcomes for all of the following objective measures: light touch, pain, temperature, vibration, upper and lower extremity function and balance. Conclusions This study is the first to provide a detailed phenotypic characterization of CIN in cancer survivors who received a platinum and/or a taxane compound. These data can serve as a benchmark for future studies of CIN in cancer survivors.

show abstract

Section: Discussionmentioning

confidence: 99%

Chemotherapy-Induced Neuropathy in Cancer Survivors

Miaskowski

Mastick

Paul

et al. 2017

Journal of Pain and Symptom Management

100

View full text Add to dashboard Cite

show abstract

“…Eighteen have been published as manuscripts [13, 17–33] and two only as abstracts [15, 16]. One is a retrospective study [33], five deal with clinical practice experiences [19, 21, 23, 26, 27], 11 are prospective single-arm clinical trials [13, 15, 17, 18, 22, 24, 25, 28, 30–32], one is a randomized open-label controlled trial [20], and two are randomized, blinded, placebo-controlled trials [16, 29]. …”

Section: Methodsmentioning

confidence: 99%

“…Sleep performance was also noted to improve significantly for the cohort. In Korea, Lee et al performed an open-label, single-arm, exploratory study involving 20 patients with CIPN, metastatic bone pain, and postsurgical neuropathic pain [32]. Pain scores decreased significantly, as did consumption of rescue opioid medication.…”

Section: Methodsmentioning

confidence: 99%

Scrambler Therapy for the management of chronic pain

Majithia

Smith

Coyne

et al. 2016

Support Care Cancer

View full text Add to dashboard Cite

Purpose Chronic pain is a widespread and debilitating condition, encountered by physicians in a variety of practice settings. Although many pharmacologic and behavioral strategies exist for the management of this condition, treatment is often unsatisfactory. Scrambler Therapy is a novel, non-invasive pain modifying technique that utilizes transcutaneous electrical stimulation of pain fibers with the intent of re-organizing maladaptive signaling pathways. This review was conducted to further evaluate what is known regarding the mechanisms and mechanics of Scrambler Therapy and to investigate the preliminary data pertaining to the efficacy of this treatment modality. Methods The PubMed/Medline, SCOPUS, EMBASE, and Google Scholar databases were searched for all articles published on Scrambler Therapy prior to November 2015. All case studies and clinical trials were evaluated and reported in a descriptive manner. Results To date, 20 reports, of varying scientific quality, have been published regarding this device; all but one small study, published only as an abstract, provided results that appear positive. Conclusion The positive findings from preliminary studies with Scrambler Therapy support that this device provides benefit for patients with refractory pain syndromes. Larger, randomized studies are required to further evaluate the efficacy of this approach.

show abstract

“…Moreover, symptomatic therapy is often largely ineffective in reducing CIPN symptoms, 16 and in the aftermath of treatment, it can have a profound effect on the quality of life (QOL) during survivorship. 17 In recent years, scrambler therapy (ST), a novel electro-analgesia device, demonstrated encouraging and positive preliminary results in NP; in fact, various trials evaluated the possible role of ST in the treatment of multiple forms of NP in adults, [18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36] and some studies included exclusively patients with CIPN. 20,28,31 A single pediatric experience described the efficacy of ST for acute pain treatment in a 12-year-old female.…”

Section: Introductionmentioning

confidence: 99%

Scrambler therapy efficacy and safety for neuropathic pain correlated with chemotherapy‐induced peripheral neuropathy in adolescents: A preliminary study

Tomasello

Pinto

Mennini

et al. 2018

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Based on these preliminary data, ST could be a good choice for adolescents with CIPN for whom pain control is difficult. ST caused total relief or dramatic reduction in CIPN pain and an improvement in quality of life, durable in follow-up. It caused no detected side effects, and can be retrained successfully. Further larger studies should be performed to confirm our promising preliminary data in pediatric patients with cancer.

show abstract

An exploratory study on the effectiveness of “Calmare therapy” in patients with cancer-related neuropathic pain: A pilot study

Cited by 23 publications

References 27 publications

Chemotherapy-Induced Neuropathy in Cancer Survivors

Chemotherapy-Induced Neuropathy in Cancer Survivors

Scrambler Therapy for the management of chronic pain

Scrambler therapy efficacy and safety for neuropathic pain correlated with chemotherapy‐induced peripheral neuropathy in adolescents: A preliminary study

Contact Info

Product

Resources

About